A phase Ib study of TriMix-MEL (ECI-006) in adjuvant metastatic melanoma patients

Trial Profile

A phase Ib study of TriMix-MEL (ECI-006) in adjuvant metastatic melanoma patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs TriMix-MEL (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jul 2017 New trial record
    • 30 Jun 2017 According to an eTheRNA Immunotherapies media release, preliminary top-line results from the study are expected in third quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top